Controlled-release doxazosin in the treatment of benign prostatic hyperplasia.
OBJECTIVE
To evaluate the effectiveness and safety of controlled-release doxazosin for benign prostatic hyperplasia (BPH).


METHODS
In this open-label, noncontrolled, observational surveillance study, 3684 men with BPH received 4-8 mg of controlled-release doxazosin gastrointestinal therapeutic system (GITS) for 6 months; 3283 (89.1%) patients completed the trial. Changes in urinary symptoms and quality of life were assessed using the International Prostate Symptom Score (IPSS). Blood pressure and adverse events were assessed.


CONCLUSIONS
After 6 months' treatment with doxazosin GITS resulted in significant improvements in IPSS. BP was reduced only in hypertensive patients. Doxazosin, GITS was well tolerated.
Hernandez
C
C
Hospital General Universitario Gregorio Marañón, Madrid, Spain. chdez@pulso.com
Duran
R
R
Jara
J
J
Castaño
I
I
Moralejo
M
M
D000368:Aged; D001794:Blood Pressure / Q000502:physiology; D017292:Doxazosin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D008297:Male; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D011788:Quality of Life; D016896:Treatment Outcome
D017430:Prostate-Specific Antigen; D017292:Doxazosin